ImmuneRegen Responds to Defense Threat Reduction Agency Request for I...(9 Met (O2)11-Substance P. Sar9 Met (O2)1...)

Date:8/23/2007

9, Met (O2)11-Substance P. Sar9, Met (O2)11-Substance P is an analog of the naturally occurring human neuropeptide Substance P, which can be found throughout the body, including in the airways of humans and many other species. All of the Company's research and development efforts are early, pre-clinical stage and Homspera(TM), as Viprovex(R) and Radilex(TM), has only undergone exploratory studies to evaluate its biological activity in small animals.

About ImmuneRegen BioSciences, Inc.

IR BioSciences Holdings, Inc., through its wholly owned subsidiary ImmuneRegen BioSciences, Inc., is a development stage biotechnology company focused on the research and development of Homspera(R) and its derivatives Radilex(TM) and Viprovex(R), which are designed to be used as countermeasures for multiple homeland security bioterrorism threats. Homspera is derived from Substance P, a naturally occurring peptide immunomodulator and homeostatic compound with the dual effect of improving pulmonary function and the stimulation of the human immune system. For more information, please visit the company's website at http://www.immuneregen.com.

Statements about the Company's future expectations, including statements about the potential for the Company's drug candidates, science and technology, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. These future events may not occur as and when expected, if at all, and, together with the Company's business, are subject to various risks and uncertainties. The Company's actual results could differ materially from expect
'/>"/>

SOURCE ImmuneRegen BioSciences, Inc. Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related biology technology :

1. Third Wave responds to Digene patent lawsuit
2. Epic responds to critics of electronic record installation
3. Small Tree Communications awarded $2.85M defense contract
4. Research consortium aims to bring security and defense contracts to Wisconsin
5. MATC student team wins cyber defense contest
6. National Bio and Agro Defense fits Wisconsin
7. Chippewa Valley firms land more defense work
8. Wisconsins failure to attract federal defense dollars crimps tech economy
9. Defense contract helps Plexus gain record profits
10. Chippewa Valley to get $46 million in defense spending
11. Wisconsins untapped defense might: why saving military bases is just a start